Literature DB >> 2802312

Virus-specific cellular blastogenesis and interleukin-2 production in swine after recovery from African swine fever.

T Scholl1, J K Lunney, C A Mebus, E Duffy, C L Martins.   

Abstract

Animals recovered from viral diseases represent an important model to study the host cellular and humoral immune responses to the etiologic agents. This is particularly important for African swine fever virus (ASFV) infections in which antibodies have little or no virus-neutralizing effect. Pigs surviving experimental infection with the naturally occurring low-virulent, nonhemadsorbing ASFV/NH/P68 (NHV) isolate did, however, exhibit virus-specific T-cell activities, as measured by a variety of assays. A strong virus-induced, antigen-specific blastogenic response was observed only with blood mononuclear cells (BMC) from ASF-recovered swine, whereas cells from recovered and naive swine responded similarly to the mitogens concanavalin A and phytohemagglutinin. The ASFV-induced blastogenesis was dependent on virus dose and on the presence of adherent cells. Blood mononuclear cells cultured with antigenically related hemadsorbing ASFV isolates of different virulence characteristics, the highly virulent L60 isolate and moderately virulent DRII isolate, exhibited a similar magnitude of blastogenesis to cells infected with the low-virulent NHV isolate. Virus-infected cells proved to be an efficient inducer of interleukin-2 (IL-2) activity to cells from recovered swine, but not from naive swine, whereas T-cell-specific lectins induced production of similar amounts of IL-2 activity from cells of naive and recovered swine. Correlated with the appearance of virus-induced IL-2 activity in the culture supernatant was the induction of promiscuous killing in cells exposed to prolonged (7 days) virus stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802312

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  African swine fever virus specific porcine cytotoxic T cell activity.

Authors:  C L Martins; M J Lawman; T Scholl; C A Mebus; J K Lunney
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

2.  Ultrastructural study of the renal tubular system in acute experimental African swine fever: virus replication in glomerular mesangial cells and in the collecting ducts.

Authors:  J C Gómez-Villamandos; J Hervás; A Méndez; L Carrasco; C J Villeda; P J Wilkinson; M A Sierra
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 3.  The lesional changes and pathogenesis in the kidney in African swine fever.

Authors:  J Hervás; J C Gómez-Villamandos; A Méndez; L Carrasco; M A Sierra
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

4.  Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3.

Authors:  Pedro J Sánchez-Cordón; Dave Chapman; Tamara Jabbar; Ana L Reis; Lynnette Goatley; Christopher L Netherton; Geraldine Taylor; Maria Montoya; Linda Dixon
Journal:  Antiviral Res       Date:  2016-11-28       Impact factor: 5.970

Review 5.  African swine fever vaccines: a promising work still in progress.

Authors:  Laia Bosch-Camós; Elisabeth López; Fernando Rodriguez
Journal:  Porcine Health Manag       Date:  2020-07-02

6.  The low-virulent African swine fever virus (ASFV/NH/P68) induces enhanced expression and production of relevant regulatory cytokines (IFNalpha, TNFalpha and IL12p40) on porcine macrophages in comparison to the highly virulent ASFV/L60.

Authors:  S Gil; N Sepúlveda; E Albina; A Leitão; C Martins
Journal:  Arch Virol       Date:  2008-09-12       Impact factor: 2.574

Review 7.  Approaches and Perspectives for Development of African Swine Fever Virus Vaccines.

Authors:  Marisa Arias; Ana de la Torre; Linda Dixon; Carmina Gallardo; Ferran Jori; Alberto Laddomada; Carlos Martins; R Michael Parkhouse; Yolanda Revilla; Fernando And Jose-Manuel Rodriguez
Journal:  Vaccines (Basel)       Date:  2017-10-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.